Li Mu-xing, Bi Xin-yu, Huang Zhen, Zhao Jian-jun, Han Yue, Li Zhi-Yu, Zhang Ye-fan, Li Yuan, Chen Xiao, Hu Xu-hui, Zhao Hong, Cai Jian-qiang
Department of Abdominal Surgical Oncology, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), NO.17, Panjiayuan Nanli, Beijing, 100021, P. R. China.
Department of Radiofrequency Ablation, Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College (CAMS & PUMC), NO.17, Panjiayuan Nanli, Beijing, 100021, P. R. China.
PLoS One. 2015 May 29;10(5):e0127356. doi: 10.1371/journal.pone.0127356. eCollection 2015.
The definite prognostic role of p-STAT3 has not been well defined. We performed a meta-analysis evaluating the prognostic role of p-STAT3 expression in patients with digestive system cancers.
We searched the available articles reporting the prognostic value of p-STAT3 in patients with cancers of the digestive system, mainly including colorectal cancer, gastric cancer, hepatocellular carcinoma, esophagus cancer and pancreatic cancer. The pooled hazard ratios (HRs) with 95 % confidence intervals (95 % CIs) of overall survival (OS) and disease-free survival (DFS) were used to assess the prognostic role of p-STAT3 expression level in cancer tissues. And the association between p-STAT3 expression and clinicopathological characteristics was evaluated.
A total of 22 studies with 3585 patients were finally enrolled in the meta-analysis. The results showed that elevated p-STAT3 expression level predicted inferior OS (HR = 1.809, 95% CI: 1.442-2.270, P < 0.001) and DFS (HR = 1.481, 95% CI: 1.028-2.133, P = 0.035) in patients with malignant cancers of the digestive system. Increased expression of p-STAT3 is significantly related with tumor cell differentiation (Odds ratio (OR) = 1.895, 95% CI: 1.364-2.632, P < 0.001) and lymph node metastases (OR = 2.108, 95% CI: 1.104-4.024, P = 0.024). Sensitivity analysis suggested that the pooled HR was stable and omitting a single study did not change the significance of the pooled HR. Funnel plots and Egger's tests revealed there was no significant publication bias in the meta-analysis.
Phospho-STAT3 might be a prognostic factor of patients with digestive system cancers. More well designed studies with adequate follow-up are needed to gain a thorough understanding of the prognostic role of p-STAT3.
p-STAT3确切的预后作用尚未明确界定。我们进行了一项荟萃分析,以评估p-STAT3表达在消化系统癌症患者中的预后作用。
我们检索了报告p-STAT3在消化系统癌症患者中预后价值的现有文章,主要包括结直肠癌、胃癌、肝细胞癌、食管癌和胰腺癌。采用总生存(OS)和无病生存(DFS)的合并风险比(HRs)及95%置信区间(95% CIs)来评估p-STAT3表达水平在癌组织中的预后作用。并评估p-STAT3表达与临床病理特征之间的关联。
最终共有22项研究、3585例患者纳入荟萃分析。结果显示,p-STAT3表达水平升高预示消化系统恶性肿瘤患者的OS(HR = 1.809,95% CI:1.442 - 2.270,P < 0.001)和DFS(HR = 1.481,95% CI:1.028 - 2.133,P = 0.035)较差。p-STAT3表达增加与肿瘤细胞分化(优势比(OR) = 1.895,95% CI:1.364 - 2.632,P < 0.001)和淋巴结转移(OR = 2.108,95% CI:1.104 - 4.024,P = 0.024)显著相关。敏感性分析表明合并HR稳定,剔除单项研究不改变合并HR的显著性。漏斗图和Egger检验显示荟萃分析中无显著发表偏倚。
磷酸化STAT3可能是消化系统癌症患者的一个预后因素。需要更多设计良好且随访充分的研究,以全面了解p-STAT3的预后作用。